1
Kevin Rodzinak
DUDKIN Vadim, FRALEY Mark E, ARRINGTON Kenneth L, LAYTON Mark E, RODZINAK Kevin J, PERO Joseph E, REIF Alexander J: Modulateurs allostériques positifs de mglur2, Positive allosteric modulators of mglur2. Merck Sharp & Dohme, DUDKIN Vadim, FRALEY Mark E, ARRINGTON Kenneth L, LAYTON Mark E, RODZINAK Kevin J, PERO Joseph E, REIF Alexander J, February 16, 2012: WO/2012/021382 (19 worldwide citation)

The present invention is directed to benzimidazolone derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 receptor is involve ...


2

3
ARRINGTON Kenneth L, DUDKIN Vadim, LAYTON Mark E, PERO Joseph E, REIF Alexander J: Modulateurs allostériques positifs de mglur2, Positive allosteric modulators of mglur2. Merck Sharp & Dohme, ARRINGTON Kenneth L, DUDKIN Vadim, LAYTON Mark E, PERO Joseph E, REIF Alexander J, December 15, 2011: WO/2011/156245 (17 worldwide citation)

The present invention is directed to 5-substituted 1,3-dihydro-2H-imidazo[4,5-b]pyridine-2-one derivatives which are positive allosteric modulators of the mGluR2 receptor, useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseas ...


4
Arrington Kenneth L, Fraley Mark E, Hartman George D: Mitotic kinesin inhibitors. Merck & Co, Arrington Kenneth L, Fraley Mark E, Hartman George D, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, July 21, 2005: WO/2005/065183 (13 worldwide citation)

The present invention relates to 2,3-diarylquinazolinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, and ...


5
Arrington Kenneth L, Dudkin Vadim Y, Fraley Mark E, Wang Cheng, Hoffman Jacob M, Kreatsoulas Constantine: Inhibitors of checkpoint kinases. Merck & Co, Arrington Kenneth L, Dudkin Vadim Y, Fraley Mark E, Wang Cheng, Hoffman Jacob M, Kreatsoulas Constantine, MERCK 126 East Lincoln Avenue Rahway New Jersey 07065 0907, December 21, 2006: WO/2006/135604 (6 worldwide citation)

The instant invention provides for compounds which comprise substituted pyridyl aminothiazoles that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of t ...


6
Arrington Kenneth L, Bilodeau Mark T, Fraley Mark E, Hartman George D, Hoffman William F, Hungate Randall W, Kim Yuntae: Tyrosine kinase inhibitors. Merck & Co, July 31, 2002: EP1226136-A2 (2 worldwide citation)

The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, athero ...


7
Arrington Kenneth L, Fraley Mark E, Garbaccio Robert M, Huang Shaei Y, Lindsley Craig W, Steen Justin T, Yang Feng: Inhibitors of checkpoint kinases. Merck & Co, Arrington Kenneth L, Fraley Mark E, Garbaccio Robert M, Huang Shaei Y, Lindsley Craig W, Steen Justin T, Yang Feng, MERCK 126 East Lincoln Avenue Rahway New Jersey 07065 0907, August 17, 2006: WO/2006/086255 (2 worldwide citation)

The instant invention provides for compounds which comprise substituted indolyl indazoles that inhibit CHK1 activity. The instant compounds provide a novel mechanism of action with unexpected advantageous properties; such unexpected advantageous properties may include increased cellular potency/solu ...


8
Arrington Kenneth L, Dudkin Vadim Y, Fraley Mark E, Garbaccio Robert M, Hartman George D, Huang Shaei Y, Kreatsoulas Constantine, Tasber Edward S: Inhibitors of checkpoint kinases. Merck & Co, Arrington Kenneth L, Dudkin Vadim Y, Fraley Mark E, Garbaccio Robert M, Hartman George D, Huang Shaei Y, Kreatsoulas Constantine, Tasber Edward S, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, January 18, 2007: WO/2007/008502 (2 worldwide citation)

The instant invention provides for compounds which comprise benzoisoquinolinones and aza derivatives that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in nee ...


9
Arrington Kenneth L, Fraley Mark E, Hanney Barbara, Kim Yuntae, Spencer Keith L: Tyrosine kinase inhibitors. Merck & Co, Arrington Kenneth L, Fraley Mark E, Hanney Barbara, Kim Yuntae, Spencer Keith L, MERCK 126 East Lincoln AvenueRahway NJ 07065 0907, March 27, 2003: WO/2003/024969 (1 worldwide citation)

The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogenesis, cancer, tumor growth, athero ...


10
Arrington Kenneth L, Fraley Mark E, Hartman George D: Mitotic kinesin inhibitors. Merck & Co, Arrington Kenneth L, Fraley Mark E, Hartman George D, MERCK 126 East Lincoln Avenue Rahway NJ 07065 0907, July 7, 2005: WO/2005/061518 (1 worldwide citation)

The present invention relates to 2-phenylthienylpyrimidinone compounds that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The invention also related to compositions which comprise these compounds, ...



Click the thumbnails below to visualize the patent trend.